Skip to main content
. Author manuscript; available in PMC: 2011 Jun 30.
Published in final edited form as: Int J Pharm. 2010 Apr 21;393(1-2):197–202. doi: 10.1016/j.ijpharm.2010.04.003

Figure 1. Significant decrease of immunogenicity when the BSA-conjugated nanoparticles were stored as an aqueous suspension.

Figure 1

BSA-conjugated nanoparticles (BSA-NPs) were stored at room temperature in an aqueous suspension (BSA-NPs, Aq/RT) for upto a month, and the anti-BSA IgG titer induced by them was compared to that of freshly prepared BSA-NPs. Data shown are mean ± S.D. from group of 5 mice (anti-log2 values).

HHS Vulnerability Disclosure